# Strength training and sarcopenia—a mandatory link: focus on MicroRNAs

**Authors:** Erika Cione, Diana Marisol Abrego-Guandique, Aldo Chiari, Roberto Cannataro

PMC · DOI: 10.3389/fragi.2025.1554340 · 2025-07-30

## TL;DR

This review highlights the role of strength training and microRNAs in managing sarcopenia, a condition causing muscle loss in older adults.

## Contribution

The paper emphasizes microRNAs as potential biomarkers and therapeutic targets for sarcopenia.

## Key findings

- MicroRNAs regulate protein synthesis and differ in sarcopenia patients.
- Monitoring specific microRNA signatures could provide early detection of sarcopenia.
- MicroRNAs may serve as a foundation for developing new drugs for sarcopenia.

## Abstract

Over the last 20 years, increased life expectancy has been observed in men and women, resulting in a rise in the prevalence of diseases among the aging population. From this, sarcopenia has an estimated prevalence of 10%–16% of older people worldwide. Losing strength and muscle mass in the 65–70 age group represents a significant public health problem. In this review, we emphasize the essential importance of strength training in managing sarcopenia, highlighting the role of microRNAs, small nucleotides that were the subject of last year’s Nobel Prize in Physiology or Medicine. These microRNAs regulate protein synthesis and are present in all biological fluids. Some of them are expressed differently by subjects affected by sarcopenia (as happens in various forms of cancer or other diseases). Therefore, monitoring a specific signature of microRNAs can better clarify the etiopathology of sarcopenia, providing an early biomarker for sarcopenia (currently, there are some hypotheses, but none is well recognized), and even serve as the basis for the development of drugs.

Diagram illustrating the process of miRNA biogenesis and its pathways. In the nucleus, RNA polymerase II transcribes miRNA genes into pri-miRNA, processed by Drosha-DGCR8 to pre-miRNA, exported by Exportin-5. In the cytoplasm, Dicer with Ago and TRBP forms the RISC complex, leading to three outcomes: inhibition of translation, mRNA degradation, or translocation to dendrites and axons. The diagram includes exocytosis involving multivesicular endosomes and exosomes.

## Full-text entities

- **Genes:** DROSHA (drosha ribonuclease III) [NCBI Gene 29102] {aka ETOHI2, HSA242976, RANSE3L, RN3, RNASE3L, RNASEN}, Mstn (myostatin) [NCBI Gene 17700] {aka Cmpt, Gdf8}, FSD1 (fibronectin type III and SPRY domain containing 1) [NCBI Gene 79187] {aka GLFND, MIR1}, MIR34A (microRNA 34a) [NCBI Gene 407040] {aka MIRN34A, miRNA34A, mir-34, mir-34a}, PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891] {aka LEM6, PGC-1(alpha), PGC-1alpha, PGC-1v, PGC1, PGC1A}, MIR223 (microRNA 223) [NCBI Gene 407008] {aka MIRN223, miRNA223, mir-223}, MIR1245A (microRNA 1245a) [NCBI Gene 100302219] {aka MIR1245, MIRN1245, hsa-mir-1245, hsa-mir-1245a, mir-1245a}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, MIR193B (microRNA 193b) [NCBI Gene 574455] {aka MIRN193B, mir-193b}, MIR451A (microRNA 451a) [NCBI Gene 574411] {aka MIR451, MIRN451, hsa-mir-451, hsa-mir-451a, mir-451a}, Pax7 (paired box 7) [NCBI Gene 18509] {aka Pax-7}, MIR214 (microRNA 214) [NCBI Gene 406996] {aka MIRN214, miRNA214, mir-214}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, NPM1 (nucleophosmin 1) [NCBI Gene 4869] {aka B23, NPM}, Igf1 (insulin-like growth factor 1) [NCBI Gene 16000] {aka C730016P09Rik, Igf-1, Igf-I}, Myod1 (myogenic differentiation 1) [NCBI Gene 17927] {aka MYF3, MyoD, Myod-1, bHLHc1}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, Myf6 (myogenic factor 6) [NCBI Gene 17878] {aka MRF4, bHLHc4, herculin}, Myf5 (myogenic factor 5) [NCBI Gene 17877] {aka B130010J22Rik, Myf-5, bHLHc2}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, DICER1 (dicer 1, ribonuclease III) [NCBI Gene 23405] {aka DCR1, Dicer, Dicer1e, GLOW, HERNA, K12H4.8-LIKE}, DGCR8 (DGCR8 microprocessor complex subunit) [NCBI Gene 54487] {aka C22orf12, DGCRK6, Gy1, pasha}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, IRS1 (insulin receptor substrate 1) [NCBI Gene 3667] {aka HIRS-1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, Myog (myogenin) [NCBI Gene 17928] {aka MYF4, bHLHc3, myo}, Cdkn1b (cyclin dependent kinase inhibitor 1B) [NCBI Gene 12576] {aka Kip1, p27, p27Kip1}, Cdkn1a (cyclin dependent kinase inhibitor 1A) [NCBI Gene 12575] {aka CAP20, CDKI, CIP1, Cdkn1, P21, SDI1}, MYRF (myelin regulatory factor) [NCBI Gene 745] {aka 11orf9, C11orf9, CUGS, MMERV, MRF, NNO1}, Gdf11 (growth differentiation factor 11) [NCBI Gene 14561] {aka BMP-11, Bmp11}, MIR378A (microRNA 378a) [NCBI Gene 494327] {aka MIR378, MIRN378, hsa-mir-378, hsa-mir-378a, miRNA378}
- **Diseases:** COVID-19 (MESH:D000086382), hemolysis (MESH:D006461), falls (MESH:C537863), ALS (MESH:D000690), knee osteoarthritis (MESH:D020370), Sarcopenia (MESH:D055948), muscle atrophy (MESH:D009133), lipedema (MESH:D065134), sarcopenic condition (MESH:D020763), osteoarticular pathologies (MESH:D014394), cancer (MESH:D009369), atrophy (MESH:D001284), physical disability (MESH:D059445), loss of muscle mass, (MESH:C536030), inflammation (MESH:D007249), impaired muscle homeostasis (MESH:D009135), muscle hypertrophy (MESH:C536106), cardiovascular diseases (MESH:D002318)
- **Chemicals:** creatine (MESH:D003401), carbon (MESH:D002244), beta-carotene (MESH:D019207), gold (MESH:D006046), omega-3 fatty acids (MESH:D015525), polyphenols (MESH:D059808)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Enterovirus C (no rank) [taxon 138950], Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12343731/full.md

---
Source: https://tomesphere.com/paper/PMC12343731